TenQ · fact sheet · filings current to · price as of
Intuitive Surgical (ISRG)
A mixed picture - strengths and real weaknesses - 19 of 36 checks passed.
Latest close : $366.70, -0.8% on the day; -38.1% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $366.70 |
| Market cap | $129.5B |
| 52-week range | $332.02 - $592.85 |
| P/E | 42.4x |
| P/E, own 11-year median | 57.6x |
| P/S | 11.7x |
| Free cash flow yield | 2.5% |
| Dividend yield | - |
| Revenue (TTM) | $11.0B |
| Net income (TTM) | $3.1B |
| Free cash flow (TTM) | $3.2B |
| Gross margin | 66.7% |
| Operating margin | 31.3% |
| Return on equity | 17.3% |
| Revenue growth (1y) | +20.7% |
| Revenue CAGR (3y) | +17.4% |
| Debt / equity | - |
| Cash & short-term investments | $5.2B |
| Shares outstanding | 353.3m (cover page of the latest filing, 2026-07-16) |
The score: 19 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is ISRG stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Intuitive Surgical still growing?
Growth · 6 of 6 checks passed. The business is genuinely growing - revenue +20.7% in the last year, and it's consistent. chapter →
Does Intuitive Surgical make real money?
Quality · 5 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Intuitive Surgical survive a bad year?
Health · 4 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Intuitive Surgical hand back to shareholders?
Shareholder returns · 3 of 6 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is ISRG trending?
Trend analysis · 0 of 6 checks passed. The market is voting against it right now - a falling trend on most measures. chapter →
Are insiders buying or selling ISRG?
Open-market buys: $0.00 · sells: $13M, across the recent Form 4 filings. detail →
Other instruments and medical devices we cover: Thermo Fisher Scientific (TMO) · DexCom (DXCM) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.